SCHEMBL7500671

SCHEMBL7500671

NC(=O)NOS(=O)(=O)c1ccccc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 3/20 0.46
MEN1 O00255 1/20 0.46
CA1 P00915 2/20 0.42
CA2 P00918 2/20 0.42
MMP1 P03956 1/20 0.42
MMP2 P08253 1/20 0.42
MMP9 P14780 1/20 0.42
MMP8 P22894 1/20 0.42
MMP13 P45452 1/20 0.42
MAPT P10636 4/20 0.41
SMN1; SMN2 Q16637 2/20 0.41
CA12 O43570 1/20 0.41
CA3 P07451 1/20 0.41
CA4 P22748 1/20 0.41
CA6 P23280 1/20 0.41
CA5A P35218 1/20 0.41
CA7 P43166 1/20 0.41
PLA2G7 Q13093 1/20 0.41
CA9 Q16790 1/20 0.41
CA13 Q8N1Q1 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Water SCHEMBL27768309 0.98 KMT2A (0.44) KMT2AMEN1CA1CA2MMP1
SCHEMBL11798964 0.86 CA1 (0.43) KMT2AMEN1CA1CA2MMP1
SCHEMBL7765292 0.82 CA1 (0.45) KMT2ACA1CA2MMP1MMP2
SCHEMBL28081700 0.82 BCAT1 (0.50) KMT2AMEN1CA1CA2MMP1
SCHEMBL27752562 0.81 MAPT (0.54) KMT2AMEN1CA1CA2MAPT
SCHEMBL11794766 0.81 F2 (0.49) KMT2AMEN1CA1CA2MMP1
SCHEMBL28387205 0.79 SLC1A3 (0.39) KMT2ACA1CA2MMP1MMP2
SCHEMBL27600480 0.79 PRMT1 (0.40) KMT2AMEN1CA1CA2MMP2
SCHEMBL29126156 0.78 TGM2 (0.46) CA1CA2MMP1MMP2MMP9
SCHEMBL28763397 0.78 F2 (0.53) CA1CA2MMP1MMP2MMP9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-106573913-A Acid addition salts of Trk inhibiting compounds 小野药品工业株式会社 2017-04-19 CN claimed
CN-101448796-B Salts and crystal modifications thereof NOVARTIS AG 2012-09-26 CN claimed
CN-101448796-A Salts and crystal modifications thereof NOVARTIS AG (CH) 2009-06-03 CN claimed
CN-1058705-C Substituted benzene sulfone urea, benzenesulfonyl thiourea its preparation, its application as medicine or diagnostic medicine and drugs containing it HOECHST AG (DE) 2000-11-22 CN claimed
CN-106573913-B Inhibit the acid-addition salts of the compound of Trk 小野药品工业株式会社 2019-11-19 CN disclosed
CN-106573913-A Acid addition salts of Trk inhibiting compounds 小野药品工业株式会社 2017-04-19 CN disclosed
CN-102015680-B New substituted indolin-2-one derivatives and use thereof as p38 mitogen-activated kinase inhibitors ALMIRALL SA 2013-11-20 CN disclosed
CN-101679413-B New 3-([1,2,4]triazolo[4,3-a]pyridin-7-yl)benzamide derivatives ALMIRALL LAB 2013-07-03 CN disclosed
CN-101448796-B Salts and crystal modifications thereof NOVARTIS AG 2012-09-26 CN disclosed
CN-102026972-A New substituted spiro[cycloalkyl-1,3'-indol]-2'(1'H)-one derivatives and their use as p38 mitogen-activated kinase inhibitors ALMIRALL SA 2011-04-20 CN disclosed
CN-102015680-A New substituted indolin-2-one derivatives and their use as p38 mitogen-activated kinase inhibitors ALMIRALL SA 2011-04-13 CN disclosed
CN-101679413-A New 3-([1,2,4]triazolo[4,3-a]pyridin-7-yl)benzamide derivatives ALMIRALL LAB 2010-03-24 CN disclosed
CN-101448796-A Salts and crystal modifications thereof NOVARTIS AG (CH) 2009-06-03 CN disclosed
CN-101268064-A Pyrazine derivatives useful as adenosine receptor antagonists ALMIRALL LAB (ES) 2008-09-17 CN disclosed
EP-1158980-A4 N-UREIDOALKYL-PIPERIDINES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY DU PONT PHARM CO (US) 2002-04-03 EP disclosed
EP-1158980-A1 N-UREIDOALKYL-PIPERIDINES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY Du Pont Pharmaceuticals Company (US) 2001-12-05 EP disclosed
WO-2000035453-A1 N-UREIDOALKYL-PIPERIDINES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY DU PONT PHARMACEUTICALS COMPANY (US) 2000-06-22 WO disclosed